These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Omalizumab in chronic inducible urticaria: A retrospective, real-life study. Fialek M; Dezoteux F; Le Moing A; Karimova E; Ramdane N; Pape E; Azib-Meftah S; Staumont-Sallé D Ann Dermatol Venereol; 2021 Dec; 148(4):262-265. PubMed ID: 34247853 [No Abstract] [Full Text] [Related]
9. Effective omalizumab interval prolongation in the treatment of chronic urticaria. Alizadeh Aghdam M; Pieterse RH; Kentie PA; Rijken F; Knulst AC; Röckmann H J Allergy Clin Immunol Pract; 2020; 8(10):3667-3668.e1. PubMed ID: 32679351 [No Abstract] [Full Text] [Related]
10. High-dose omalizumab use in patients with chronic spontaneous urticaria. Alizadeh Aghdam M; van den Broek F; Rijken F; Knulst AC; Röckmann H J Allergy Clin Immunol Pract; 2020 Apr; 8(4):1426-1427.e1. PubMed ID: 31678293 [No Abstract] [Full Text] [Related]
11. Real-life clinical practice with omalizumab in 134 patients with refractory chronic spontaneous urticaria: a single-center experience. Akdaş E; Adışen E; Öztaş MO; Aksakal AB; İlter N; Gülekon A An Bras Dermatol; 2023; 98(2):240-242. PubMed ID: 36567165 [No Abstract] [Full Text] [Related]
12. Clinical predictive factors of unresponsiveness to omalizumab in patients with chronic spontaneous urticaria. Castagna J; Bernard L; Hacard F; Delcroix F; Darrigade AS; Nicolas JF; Decullier E; Nosbaum A; Bérard F Br J Dermatol; 2020 Dec; 183(6):1124-1126. PubMed ID: 32531805 [No Abstract] [Full Text] [Related]
13. [HOW PERIPHERAL BASOPHILS IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA ARE CHANGED WITH OMALIZUMAB TREATMENT?]. Oda Y; Washio K; Mizuno M; Imamura S; Nishigori C; Fukunaga A Arerugi; 2021; 70(9):1196-1199. PubMed ID: 34759084 [No Abstract] [Full Text] [Related]
14. Anti-IL-23 treatment with tildrakizumab can be effective in omalizumab-refractory chronic spontaneous urticaria: A case series. Bonnekoh H; Kiefer L; Buttgereit T; Kolkhir P; Lütke-Eversloh M; Scheffel J; Maurer M; Metz M J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2578-2580.e1. PubMed ID: 37244440 [No Abstract] [Full Text] [Related]
15. Chronic spontaneous urticaria treated with omalizumab: what differentiates early from late responders? Asero R Eur Ann Allergy Clin Immunol; 2021 Jan; 53(1):47-48. PubMed ID: 32378398 [No Abstract] [Full Text] [Related]
16. Omalizumab in children and adolescents with chronic urticaria: A 16-week real-world study. Song XT; Chen YD; Yu M; Liu B; Zhao ZT; Maurer M Allergy; 2021 Apr; 76(4):1271-1273. PubMed ID: 33275779 [No Abstract] [Full Text] [Related]
18. Recalcitrant chronic urticaria treated with dupilumab: Report of two instances refractory to H1-antihistamines, omalizumab and cyclosporine and brief literature review. Errichetti E; Stinco G Dermatol Ther; 2021 Mar; 34(2):e14821. PubMed ID: 33506984 [No Abstract] [Full Text] [Related]
19. Effectiveness and tolerability of personalized omalizumab treatment in patients with chronic inducible urticaria. Buters TP; van der Velden WAC; Abdisalaam I; van Maaren MS; van Doorn MBA J Allergy Clin Immunol Pract; 2021 Aug; 9(8):3227-3229. PubMed ID: 33915307 [No Abstract] [Full Text] [Related]